AstraZeneca has agreed to buy biotechnology company CinCor Pharma for up to $1.8 billion to gain a promising new hypertension and kidney disease treatment.
AstraZeneca s CinCor Acquisition Looks a Good Fit morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
The result is a setback for the firm - led by chief exec Pascal Soriot (pictured) -and could affect its sales, with Imfinzi raking in nearly £2bn of revenues last year.